VNRX stock information

Sector:

Healthcare

Description:

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

VolitionRx Limited website

Current Price

$1.54

RSI

53.60

Market Capitalization:

157M

Beta:

1.716

Volume:

217,238

Analyst Target Price:

$ 7.5

Economiic Fair Price:

Earnings DateNovember 09, 2022

Report DateNovember 14, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash16.7M

Debt4.1M

EPS-0.465

Profit MarginN/A

Revenue Per Share TTM0.002

Return On Equity TTM-1.198

2019 Revenue

$ 17.1K

2020 Free Cash Flow

$ -18.4M

2019 Free Cash Flow

$ -13.3M

2018 Free Cash Flow

$ -15M

2017 Free Cash Flow

$ -13.6M

2016 Free Cash Flow

$ -9.5M

2019 Pre Tax Income

$ -16.1M

VolitionRx Limited(VNRX)